- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03342391
CEGIR 7808: Use of Unsedated Transnasal Esophagoscopy (TNE) to Monitor Dietary Management of Eosinophilic Esophagitis in Children
March 8, 2021 updated by: Children's Hospital Medical Center, Cincinnati
The purpose of this study is to test the effectiveness of utilizing Transnasal Esophagoscopy as a means of monitoring Eosinophilic Esophagitis patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A participant with an established diagnosis of EoE who is undergoing Standard of Care treatment with a four or less food elimination diet (not including or counting foods restricted at time of EoE diagnosis) OR is on topical swallowed steroid therapy with any number of foods eliminated from the diet, is in histological remission, and has been recommended as part of Standard of Care to start a single new food introduction OR remove the swallowed steroid treatment by the subject's clinical allergist or gastroenterologist will be enrolled in the study.
14-17 days after the introduction of the clinically recommended single food antigen, a TNE will be performed to assess the esophageal mucosa.
TNE will be performed every 2 weeks for six weeks (3 total TNE) to evaluate recurrence time of mucosal eosinophilia (>15 eos/HPF), other histological changes, and patient tolerance to serial TNE.
At week 6 a sedated esophagoscopy will be offered as an alternative choice to TNE if the participant chooses.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Children's Hospital Colorado
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years to 22 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant must be able to understand and provide informed consent/assent
- Males and females ages 5-22 years of age
- History of an established diagnosis of EoE
- Recent EGD or TNE (with in past 1 year) showing EoE remission (e.g. <15 x eosinophils/hpf) and currently without significant symptoms attributed to EoE.
- On a four food or less elimination diet not including or counting foods restricted at time of EoE diagnosis OR on swallowed topical steroid therapy with any number of foods eliminated from the diet.
- Female subjects of childbearing potential must have a negative pregnancy test upon study entry
- Female subjects with reproductive potential, must agree to use FDA approved methods of birth control for the duration of the study
- Children and families have desire to reintroduce potential food allergens and either the food antigen has been recommended with plans for its introduction as part of Standard of Care by the child's allergist and/or gastroenterologist OR the swallowed topical steroid therapy has been recommended to be discontinued by the child's allergist and/or gastroenterologist.
- Children and families willing to undergo unsedated serial TNE
Exclusion Criteria:
- Inability or unwillingness of a participant to give written informed consent or comply with study protocol
- Bleeding disorder
- Unwilling to undergo unsedated TNE
- Unwilling or unable to come to hospital at least 3 times over 6 weeks.
- Currently treated with a swallowed corticosteroid which is not being discontinued.
- Treated with oral corticosteroids within 8 weeks of the start of the study.
- More than one change is being made to the EoE treatment regimen (e.g., more than a single food is being reintroduced during the study period; the swallowed topical steroid is being discontinued at the same time a food is being introduced).
- EoE has been symptomatic with clinically significant symptoms attributable to EoE including dysphagia, abdominal pain or vomiting in the period since endoscopy
- The finding of uncontrolled cough, significant rhinorrhea or rhinitis obstructing nasal passages, oxygen saturations <92% (high altitude normal saturation), temperature >38 degrees Celsius, significant gastrointestinal illness within 1 week of TNE, or provider determination of significant illness during pre-procedure history and physical on the day that the TNE is planned.
- Pregnancy, breast feeding or plans to become pregnant
- Unable to complete study procedures including endoscopy.
- Allergy to any material or medicine used for procedures
- Use of investigational drugs within 16 weeks of participation
- Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Treatment Phase
Treatment Phase will evaluate the effectiveness of Transnasal Esophagoscopy (TNE) as an acceptable form of monitoring Eosinophilic Esophagitis
|
single food antigen introduction OR removal of topical swallowed steroid therapy followed by surveillance utilizing TNE
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Histological Improvement
Time Frame: 6 weeks
|
To prospectively and serially evaluate the recurrence of esophageal eosinophilia (>15 eosinophils per high power field) after a clinical single food antigen introduction OR removal of swallowed topical steroid therapy by the subject's clinical allergist or gastroenterologist in children with EoE using unsedated Transnasal Endoscopy/Esophagoscopy.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endoscopic Appearances/Histological Findings
Time Frame: 6 weeks
|
1. To identify serially the clinical (endoscopic appearances) and other histological findings (lamina propria fibrosis, mast cells, lymphocytes) associated with dietary food introductions OR swallowed topical steroid therapy removal in children with EoE.
|
6 weeks
|
Sample Size
Time Frame: 6 weeks
|
2. To determine and evaluate mucosal sample size obtained during TNE (2.0 mm or 1.2 mm forceps) compared to that obtained during those same subjects' previous traditional sedated endoscopy/esophagoscopy (2.8 mm forceps).
|
6 weeks
|
Decision to participate
Time Frame: 6 weeks
|
3. To assess family factors determining decision to complete TNE study and subject's satisfaction with serial TNE using the previously reported TNE Qualitative Questionnaire, the General Anxiety Disorder (GAD)-7 Anxiety Instrument and a structured interview.
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Joel Friedlander, M.D., Children's Hospital Colorado
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2017
Primary Completion (Actual)
August 31, 2020
Study Completion (Actual)
September 1, 2020
Study Registration Dates
First Submitted
November 9, 2017
First Submitted That Met QC Criteria
November 9, 2017
First Posted (Actual)
November 17, 2017
Study Record Updates
Last Update Posted (Actual)
March 9, 2021
Last Update Submitted That Met QC Criteria
March 8, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-0237
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eosinophilic Esophagitis
-
Children's Hospital Medical Center, CincinnatiNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsCompletedEosinophilic Esophagitis (EoE) | Eosinophilic Gastrointestinal Disorders (EGIDs)United States
-
Federico II UniversityRecruitingEsophagitis, EosinophilicItaly
-
Ann & Robert H Lurie Children's Hospital of ChicagoRecruitingEosinophilic Gastroenteritis | Eosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic Gastrointestinal DiseaseUnited States
-
Medical University of GrazRecruiting
-
AQILION ABCompletedEosinophilic Esophagitis (EoE)United Kingdom
-
Regeneron PharmaceuticalsSanofiActive, not recruitingEosinophilic Esophagitis (EoE)United States, Canada
-
ShireTakeda Development Center Americas, Inc.TerminatedEosinophilic Esophagitis (EoE)United States
-
ShireCompletedEosinophilic Esophagitis (EoE)United States
-
ShireCompleted
-
ShireCompletedEosinophilic Esophagitis (EoE)United States
Clinical Trials on Transnasal esophagoscopy
-
Vanderbilt UniversityCompleted
-
University of Illinois at ChicagoCures Within ReachRecruiting
-
Medical University of ViennaUnknownEsophagus DisorderAustria
-
IRCCS San RaffaeleUnknownTracheal Intubation MorbidityItaly
-
University of California, San FranciscoNational Spasmodic Dysphonia AssociationNot yet recruitingVocal Cord Paralysis | Globus Pharyngeus | Spasmodic Dysphonia | Aspiration | Laryngeal Disease | Presbylarynx | Sensory Neuropathy | Iatrogenic Injury | Larynx ParalysisUnited States
-
NYU Langone HealthCompletedIpsilateral Shoulder PainUnited States
-
University Hospital OstravaCompletedSquamous Cell Carcinomas of the Head and NeckCzech Republic
-
Hvidovre University HospitalGlostrup University Hospital, CopenhagenTerminated
-
Assistance Publique - Hôpitaux de ParisTerminatedRhinocerebral MucormycosisFrance
-
Youlin Yang ,MDUnknownColon Disease; | Rectal DiseaseChina